According to CymaBay Therapeutics 's latest financial reports the company's current earnings (TTM) are -$0.11 B. In 2022 the company made an earning of -$0.11 B a decrease over its 2021 earnings that were of -$90 M.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.11 B | -0.6% |
2022 | -$0.11 B | 17.78% |
2021 | -$90 M | 76.52% |
2020 | -$50.99 M | -50.41% |
2019 | -$0.11 B | 41.71% |
2018 | -$72.55 M | 163.27% |
2017 | -$27.56 M | 3.32% |
2016 | -$26.68 M | 71.75% |
2015 | -$15.53 M | -51.35% |
2014 | -$31.92 M | 216.89% |
2013 | -$10.08 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Pfizer PFE | $3.26 B | -3,200.50% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | -$5.85 B | 5,448.07% | ๐บ๐ธ USA |
Xencor XNCR | -$0.13 B | 14.30% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | -$0.7 B | 560.63% | ๐บ๐ธ USA |